Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies
Laura Doepker, Sonja Danon, Elias Harkins, Duncan Ralph, Zak A. Yaffe, Meghan Garrett, Amrit Dhar, Cassia Wagner, Megan M. Stumpf, Dana Arenz, James A. Williams, Walter Jaoko, Kishor Mandaliya, Kelly K. Lee, F. A. Matsen, Julie Overbaugh
Abstract
A prerequisite for the design of an HIV vaccine that elicits protective antibodies is understanding the developmental pathways that result in desirable antibody features. The development of antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) is particularly relevant because such antibodies have been associated with HIV protection in humans. We reconstructed the developmental pathways of six human HIV-specific ADCC antibodies using longitudinal antibody sequencing data. Most of the inferred naive antibodies did not mediate detectable ADCC. Gain of antigen binding and ADCC function typically required mutations in complementarity determining regions of one or both chains. Enhancement of ADCC potency often required additional mutations in framework regions. Antigen binding affinity and ADCC activity were correlated, but affinity alone was not sufficient to predict ADCC potency. Thus, elicitation of broadly active ADCC antibodies may require mutations that enable high-affinity antigen recognition along with mutations that optimize factors contributing to functional ADCC activity.